HRP940029B1 - Pharmaceutical composition for treating nicotine dependence - Google Patents

Pharmaceutical composition for treating nicotine dependence

Info

Publication number
HRP940029B1
HRP940029B1 HR940029A HRP940029A HRP940029B1 HR P940029 B1 HRP940029 B1 HR P940029B1 HR 940029 A HR940029 A HR 940029A HR P940029 A HRP940029 A HR P940029A HR P940029 B1 HRP940029 B1 HR P940029B1
Authority
HR
Croatia
Prior art keywords
pct
nicotine dependence
pharmaceutical composition
treating nicotine
sec
Prior art date
Application number
HR940029A
Other languages
English (en)
Inventor
Joachim Arnold Moormann
Original Assignee
Lohmann Therapie Syst Lts
Hf Arzneimittelforsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts, Hf Arzneimittelforsch Gmbh filed Critical Lohmann Therapie Syst Lts
Publication of HRP940029A2 publication Critical patent/HRP940029A2/hr
Publication of HRP940029B1 publication Critical patent/HRP940029B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
HR940029A 1993-01-23 1994-01-20 Pharmaceutical composition for treating nicotine dependence HRP940029B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301782A DE4301782C1 (de) 1993-01-23 1993-01-23 Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit

Publications (2)

Publication Number Publication Date
HRP940029A2 HRP940029A2 (en) 1997-06-30
HRP940029B1 true HRP940029B1 (en) 2000-06-30

Family

ID=6478780

Family Applications (1)

Application Number Title Priority Date Filing Date
HR940029A HRP940029B1 (en) 1993-01-23 1994-01-20 Pharmaceutical composition for treating nicotine dependence

Country Status (23)

Country Link
US (1) US5643905A (da)
EP (1) EP0680326B1 (da)
JP (1) JP3511074B2 (da)
KR (1) KR100301547B1 (da)
AT (1) ATE146677T1 (da)
AU (1) AU685075B2 (da)
CZ (1) CZ284605B6 (da)
DE (2) DE4301782C1 (da)
DK (1) DK0680326T3 (da)
ES (1) ES2098920T3 (da)
GR (1) GR3022862T3 (da)
HR (1) HRP940029B1 (da)
HU (1) HU221159B1 (da)
IL (1) IL108234A (da)
MY (1) MY111260A (da)
NO (1) NO306894B1 (da)
NZ (1) NZ259858A (da)
PL (1) PL174812B1 (da)
SI (1) SI9400028A (da)
SK (1) SK282247B6 (da)
WO (1) WO1994016708A1 (da)
YU (1) YU48559B (da)
ZA (1) ZA94413B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
DE69912311T2 (de) * 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
DE10119862A1 (de) 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
EP3473251B1 (en) 2002-12-20 2023-12-13 NicoNovum AB A nicotine-cellulose combination
JP2006519225A (ja) * 2003-02-27 2006-08-24 社団法人芝蘭会 依存症治療用医薬組成物
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
WO2005115471A2 (en) * 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
KR101831463B1 (ko) 2010-03-26 2018-02-22 필립모리스 프로덕츠 에스.에이. 비흡연성 담배 제품의 소비 시 감각 자극의 억제
CN101829068A (zh) * 2010-05-06 2010-09-15 徐州市光合生物营养品有限公司 一种水溶性药物缓释片及其制备方法
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
US10335378B2 (en) 2013-03-15 2019-07-02 Altria Client Services Llc Inhibition of central nervous system effects from smoking and sensory effects from smoking
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
DE3843239C1 (da) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
ATE183084T1 (de) * 1991-05-14 1999-08-15 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren

Also Published As

Publication number Publication date
NO952906D0 (no) 1995-07-21
YU48559B (sh) 1998-11-05
HU221159B1 (en) 2002-08-28
AU5881894A (en) 1994-08-15
IL108234A0 (en) 1994-04-12
CZ284605B6 (cs) 1999-01-13
YU2494A (sh) 1997-01-08
DK0680326T3 (da) 1997-06-23
SK282247B6 (sk) 2001-12-03
KR960700061A (ko) 1996-01-19
DE4301782C1 (de) 1994-08-25
MY111260A (en) 1999-10-30
HUT72670A (en) 1996-05-28
NO306894B1 (no) 2000-01-10
NO952906L (no) 1995-07-21
ES2098920T3 (es) 1997-05-01
ZA94413B (en) 1994-09-09
GR3022862T3 (en) 1997-06-30
HU9501964D0 (en) 1995-09-28
NZ259858A (en) 1997-03-24
US5643905A (en) 1997-07-01
DE59401401D1 (de) 1997-02-06
ATE146677T1 (de) 1997-01-15
JPH08505633A (ja) 1996-06-18
SI9400028A (en) 1994-09-30
SK89095A3 (en) 1996-05-08
EP0680326B1 (de) 1996-12-27
KR100301547B1 (ko) 2001-10-22
PL174812B1 (pl) 1998-09-30
PL309604A1 (en) 1995-10-30
CZ184395A3 (en) 1996-02-14
AU685075B2 (en) 1998-01-15
HRP940029A2 (en) 1997-06-30
JP3511074B2 (ja) 2004-03-29
WO1994016708A1 (de) 1994-08-04
EP0680326A1 (de) 1995-11-08
IL108234A (en) 1996-10-31

Similar Documents

Publication Publication Date Title
AU685075B2 (en) Pharmaceutical composition for treating nicotine dependence
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
GR3024157T3 (en) Use of parathormone, of its biologically active fragments and of related peptides for treatment of pregnancy.
MY124465A (en) Reduction of infarct volume using citicoline
EP0744176A3 (en) Methods for inhibiting bone loss
NZ268110A (en) Use of ropivacaine salt in pharmaceutical compositions for the treatment of pain with sensoric block and minimal motor blockage
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance
GR3034142T3 (en) Composition for the treatment or prevention of herpes
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
HUT70521A (en) Process to prepare pharmaceutical comps. again amyloidosis
HUP9903375A2 (hu) Olanzapint és fájdalomcsillapító hatóanyagot tartalmazó szinergista hatású gyógyszerkészítmények
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
CA2153570A1 (en) Pharmaceutical composition for treating nicotine dependence
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110119

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20120121